F. Barlesi

发表

Illness representations and quality of life in French patients suffering from lung cancer

N. Masson, L. Dany, P. Cannone, 2020, Psychology, health & medicine.

Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial

J. Blay, I. Bièche, G. Ferretti, 2016 .

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

H. Groen, Bruce E. Johnson, J. Rigas, 2016, The Lancet. Oncology.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

C. Rudin, S. Gettinger, E. Felip, 2015, The New England journal of medicine.

In vitro and in vivo methotrexate disposition in alveolar macrophages: comparison of pharmacokinetic parameters of two formulations.

F. Barlesi, C. Doddoli, O. Ghez, 2005, International journal of pharmaceutics.

Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Paul Baas, Ignacio I. Wistuba, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Computational oncology — mathematical modelling of drug regimens for precision medicine

Nicolas André, Joseph Ciccolini, Dominique Barbolosi, 2016, Nature Reviews Clinical Oncology.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

R. Govindan, J. Soria, G. Weiss, 2017, British Journal of Cancer.

Cytology-based treatment decision in primary lung cancer: is it accurate enough?

L. Sakr, F. Barlesi, A. Loundou, 2012, Lung cancer.

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.

O. Corneloup, G. Ferretti, D. Planchard, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung

B. Chetaille, F. Barlesi, C. Doddoli, 2005, British Journal of Cancer.

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

S. Gettinger, E. Felip, E. Vokes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation de la version française du Princess Margaret Hospital patient satisfaction with doctor questionnaire (PMH/PSQ-MD), le F-PMH/PSQ MD

A. Loundou, P. Auquier, F. Barlesi, 2006 .

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

F. Barlesi, P. Tomasini, L. Greillier, 2018, Translational lung cancer research.

Second-line treatment for advanced non-small cell lung cancer: a systematic review.

J. Pujol, F. Barlesi, W. Jacot, 2006, Lung cancer.

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.

J. Mancini, F. Barlesi, F. Roux, 2004, Respiratory medicine.

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL

K. Baumstarck, P. Auquier, O. Chinot, 2017, Health and Quality of Life Outcomes.

Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma

F. Barlesi, A. Scherpereel, P. Thomas, 2007, Cancer.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Smit, E. Felip, 2012 .

Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?

B. Chetaille, F. Barlesi, R. Giudicelli, 2005, European Journal of Cardio-Thoracic Surgery.

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.

Diego Saldana Miranda, L. Bubendorf, L. Paz-Ares, 2022, Lung cancer.

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.

M. Socinski, S. Novello, F. Barlesi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?

F. Barlesi, P. Tomasini, C. Travert, 2020, Translational lung cancer research.

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.

O. Molinier, J. Mazières, G. Zalcman, 2020, European journal of cancer.

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

L. Paz-Ares, F. Barlesi, M. Reck, 2019, Lung cancer.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

A. Drilon, J. Neal, H. Wakelee, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2019, Translational cancer research.

Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies.

F. Barlesi, S. Burtey, T. Chevalier, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC

P. Hegde, Keunchil Park, D. Gandara, 2017 .

Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

P. Hegde, F. Hirsch, D. Gandara, 2017, Pneumologie.

Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2018, Expert review of anticancer therapy.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

N. Girard, O. Molinier, M. Denis, 2019, Clinical lung cancer.

[Global brain metastases management strategy: a multidisciplinary-based approach].

S. Taillibert, N. Reyns, F. Barlesi, 2015, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Local anesthetics elicit immune-dependent anticancer effects

P. van Endert, O. Kepp, G. Kroemer, 2022, Journal for ImmunoTherapy of Cancer.

Jet exhaust particles alter human dendritic cell maturation

P. Bongrand, F. Barlesi, J. Vitte, 2011, Inflammation Research.

Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non-Small Cell Lung Cancer

F. Barlesi, J. Mochel, J. Ciccolini, 2019, bioRxiv.

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

A. Cohen-Solal, A. Cohen, F. Barlesi, 2020, Journal of the American Heart Association.

Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.

F. Barlesi, L. Bonello, M. Laine, 2017, International journal of cardiology.

Adrenal surgery for oligometastatic tumors improves survival in selected cases.

F. Barlesi, P. Tomasini, F. Sebag, 2017, Journal of visceral surgery.

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

J. Mazières, J. Merlio, F. Escande, 2020, JTO clinical and research reports.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

P. Auquier, J. Pujol, F. Barlesi, 2015, Interactive cardiovascular and thoracic surgery.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

F. Barlesi, C. Chouaid, J. Barth, 2018, Lung cancer.

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

A. Drilon, T. Wilson, R. Doebele, 2022, Molecular oncology.

Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged > 80 years.

F. Barlesi, C. Doddoli, P. Thomas, 2007, Clinical lung cancer.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized Information before Thoracic Surgery

P. Auquier, F. Barlesi, A. Loundou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The place of patient satisfaction in quality assessment of lung cancer thoracic surgery.

P. Auquier, L. Boyer, F. Barlesi, 2005, Chest.

Diagnostic et bilan d’extension des cancers broncho-pulmonaires

F. Barlesi, 2011 .

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

G. Scagliotti, F. Shepherd, S. Novello, 2018, The oncologist.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

Preoperative psychological global well being index (PGWBI) predicts postoperative quality of life for patients with non-small cell lung cancer managed with thoracic surgery.

P. Auquier, F. Barlesi, A. Loundou, 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Bronchioloalveolar carcinoma: myths and realities in the surgical management.

B. Chetaille, F. Barlesi, R. Giudicelli, 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

B. Milleron, F. Barlesi, C. Chouaid, 2010 .

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

G. Scagliotti, H. Wakelee, F. Hirsch, 2022, Journal of Thoracic Oncology.

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

F. Barlesi, J. Mochel, J. Ciccolini, 2019, CPT: pharmacometrics & systems pharmacology.

AI-based multi-modal integration (ScanCov scores) of clinical characteristics, lab tests and chest CTs improves COVID-19 outcome prediction of hospitalized patients

Fabien, M. Sefta, T. Clozel, 2020 .

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

I. Soubeyran, A. Italiano, J. Soria, 2022, Journal for ImmunoTherapy of Cancer.

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

F. Barlesi, V. Moreno, E. Chartash, 2022, Cancer Immunology, Immunotherapy.

Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer.

P. Auquier, F. Barlesi, A. Loundou, 2007, Clinical lung cancer.

P3-220: Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer

P. Auquier, F. Barlesi, A. Loundou, 2007 .

Reply to Johnson

F. Barlesi, C. Doddoli, P. Thomas, 2004 .

[Lung neuroendocrine large-cell carcinoma in young women - An unusual presentation].

F. Barlesi, P. Tomasini, L. Greillier, 2017, Revue des maladies respiratoires.

[Lung neuroendocrine large cell carcinoma in young women. An unusual presentation].

F. Barlesi, P. Tomasini, L. Greillier, 2017, Revue des maladies respiratoires.

Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy.

F. Barlesi, R. Giudicelli, P. Fuentes, 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Vascular Stenting for Palliation of Superior Vena cava Obstruction in Non-Small-Cell Lung Cancer Patients: A Future ‘Standard’ Procedure?

F. Barlesi, C. Doddoli, L. Greillier, 2004, Respiration.

Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery.

B. Chetaille, L. Garbe, F. Barlesi, 2004, The Annals of thoracic surgery.

Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC

G. Scagliotti, L. Sequist, F. Shepherd, 2014 .

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

H. Groen, J. Rigas, D. Planchard, 2015 .

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

F. Barlesi, N. Vey, C. Massard, 2022, ESMO open.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

R. Govindan, Dong-Wan Kim, B. Cho, 2018, Lung cancer.

treatable with surgery Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially

B. Chetaille, L. Garbe, F. Barlesi, 2013 .

[Which type of diagnostic and pretreatment sampling should be chosen and for which patient?].

F. Barlesi, S. Marco, 2010, Annales de pathologie.

An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.

F. Barlesi, J. Ciccolini, D. Taieb, 2016, The British journal of radiology.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

O. Molinier, P. Dumont, W. Hilgers, 2018, ESMO Open.

Gemcitabine‐induced severe pulmonary toxicity

F. Barlesi, P. Villani, C. Doddoli, 2004, Fundamental & clinical pharmacology.

AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

F. Barlesi, V. Gorbunova, A. Vikström, 2011 .

MEDI 4736 (durvalumab) in non-small cell lung cancer

F. Barlesi, Arnaud Jeanson, 2017, Expert opinion on biological therapy.

B. Milleron, O. Molinier, D. Moro-Sibilot, 2015, Journal of geriatric oncology.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

H. Groen, A. Chella, M. Ahn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice

F. Barlesi, R. Giorgi, P. Vanelle, 2018, Journal of chemotherapy.

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.

N. Girard, F. Bertucci, P. Gestraud, 2022, Lung cancer.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

J. Vansteenkiste, F. Barlesi, B. Besse, 2019, Lung Cancer.

Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?

J. Régis, F. Barlesi, P. Tomasini, 2017, World neurosurgery.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

P. Lamy, J. Pujol, G. Zalcman, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

J. Soria, J. Mazières, J. Trédaniel, 2015, Clinical Cancer Research.

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.

Mark Robson, A. Stenzinger, J. Reis-Filho, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

J. Mazières, W. Hilgers, F. Barlesi, 2021, ESMO open.

Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials

J. Daurès, J. Pujol, F. Barlesi, 2005 .

Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?

F. Barlesi, A. Loundou, P. Thomas, 2020, Lung Cancer.

Biologic staging of non-small-cell lung cancer: prospect or proposal?

J. Pujol, F. Barlesi, W. Jacot, 2005, Clinical lung cancer.

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question—to treat or not to treat?

M. Dietel, F. López-Ríos, F. Barlesi, 2018, ESMO Open.

Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective

F. Barlesi, P. Villani, C. Doddoli, 2005, Fundamental & clinical pharmacology.

Lung cancer: moving forward with tailored strategies.

F. Barlesi, 2008, The Lancet. Oncology.

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer

G. Scagliotti, S. Novello, E. Felip, 2014 .

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.

G. Scagliotti, E. Felip, A. Santoro, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The place of pemetrexed in the management of non-small-cell lung cancer patients

F. Barlesi, P. Tomasini, L. Greillier, 2013, Expert review of anticancer therapy.

Non-small cell lung cancer-smokers or non-smokers, does it matter?

F. Barlesi, pierre-Marie Martin, I. Nanni-Metellus, 2009, Lung cancer.

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

R. Govindan, S. Ramalingam, V. Velcheti, 2021, The New England journal of medicine.

[Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].

F. Barlesi, L. Greillier, Fabrice Barlesi, 2012, Revue des maladies respiratoires.

Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.

F. Barlesi, P. Tomasini, 2020, The Lancet. Oncology.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

J. Riess, E. Felip, L. Paz-Ares, 2019, Clinical lung cancer.

Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.

C. Marquette, J. Thariat, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

L. Crinò, N. Rizvi, M. Hellmann, 2016 .

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

M. Kris, M. Socinski, J. Soria, 2014 .

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

M Paesmans, O. Molinier, M. Paesmans, 2004, British Journal of Cancer.

Completion pneumonectomy in cancer patients: experience with 55 cases.

B. Chetaille, F. Barlesi, R. Giudicelli, 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits.

F. Barlesi, R. Giudicelli, P. Fuentes, 2005, The Journal of thoracic and cardiovascular surgery.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.

P. Jänne, A. Kohlmann, L. Crinò, 2016 .

Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.

O. Molinier, G. Zalcman, P. Dumont, 2016 .

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.

J. Pujol, F. Barlesi, 2005, Lung cancer.

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

D. Gandara, F. Ciardiello, C. Barrios, 2016 .

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

E. Quoix, B. Mennecier, G. R. Ferretti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[Biomarkers for today and tomorrow in thoracic oncology].

F. Barlesi, L. Greillier, 2010, Revue des maladies respiratoires.

Reply to B.M. Strebel.

H. Groen, M. Ahn, J. Aerts, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

A. Bezjak, J. V. van Meerbeeck, C. Faivre-Finn, 2017, The Lancet. Oncology.

CYP1A1 Induction in the Colon by Serum: Involvement of the PPARα Pathway and Evidence for a New Specific Human PPREα Site

J. Pascussi, F. Barlesi, C. Ginies, 2011, PloS one.

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

K. Harrington, E. Copson, K. Rieger-Christ, 2022, JCO clinical cancer informatics.

Prolonged SARS-CoV-2 RNA virus shedding and 1 lymphopenia are hallmarks of COVID-19 in cancer 2 patients with poor prognosis 3 4

L. Zitvogel, G. Kroemer, Gabriel, 2021 .

Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC

G. Giaccone, F. Kruyt, F. Barlesi, 2008, International Journal of Cancer.

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.

J. Grob, A. Cohen, F. Barlesi, 2017, Circulation.

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Robert W. Hsieh, Melissa L. Johnson, L. Paz-Ares, 2020 .

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

E. Felip, L. Crinò, N. Rizvi, 2016 .

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

H. Groen, L. Urban, E. Felip, 2019, Journal of Thoracic Oncology.

Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

K. Syrigos, Keunchil Park, H. Borghaei, 2020 .

Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2019, Journal of Cancer Therapy.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Robert W. Hsieh, Melissa L. Johnson, J. Yang, 2022, The Lancet. Oncology.

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

F. Hirsch, Keunchil Park, D. Gandara, 2021, Clinical lung cancer.

Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).

C. Marquette, S. Leroy, M. Denis, 2019, Clinical lung cancer.

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

D. Gandara, G. Tarcic, F. Barlesi, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Precision follow-up for resected non-small-cell lung cancer: is it ready for prime time?

F. Barlesi, O. Mercier, 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay

C. Marquette, J. Thariat, J. Mazières, 2020, Annals of translational medicine.

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).

C. Marquette, F. Barlesi, J. Benzaquen, 2020, Lung cancer.

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

E. Copson, K. Rieger-Christ, O. Michielin, 2022, Cancers.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Keunchil Park, D. Gandara, J. von Pawel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.

C. Schumann, B. Asselain, D. Moro-Sibilot, 2021, Lung cancer.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.

Keunchil Park, D. Gandara, J. Mazières, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

R. Herbst, M. Ahn, E. Felip, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

R. Govindan, R. Ramlau, M. Krzakowski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

N. Girard, E. Devin, J. Muir, 2022, The Lancet. Oncology.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

P. Jänne, E. Smit, E. Felip, 2020 .

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Drilon, R. Doebele, R. Dziadziuszko, 2018, Journal of Thoracic Oncology.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

T. Lynch, I. Bondarenko, F. Barlesi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

Keunchil Park, D. Gandara, F. Ciardiello, 2017 .

Impact of COVID-19 on healthcare organisation and cancer outcomes

D. Planchard, M. Ducreux, S. Michiels, 2021, European Journal of Cancer.

Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.

T. de Baère, J. Soria, C. Robert, 2022, European journal of cancer.

Caring for patients with cancer in the COVID-19 era

S. Fröhling, D. Jäger, J. Bergh, 2020, Nature Medicine.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2018 .

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

S. Peters, E. Felip, H. Borghaei, 2017 .

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.

H. Groen, A. Chella, M. Ahn, 2013 .

9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

M. Ahn, J. Burgers, F. Barlesi, 2011 .

1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

A. Drilon, T. Wilson, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

D. Planchard, N. Chaput, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

D. Planchard, J. Soria, G. Viscardi, 2020 .

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

F. Barlesi, P. Tomasini, J. Ciccolini, 2022, Cancer Chemotherapy and Pharmacology.

Predictive molecular pathology in non–small cell lung cancer in France: The past, the present and the perspectives

P. Laurent-Puig, J. Sabourin, J. Deleuze, 2020, Cancer cytopathology.

[Acute pulmonary toxicity due to gemcitabine: a role for asbestos exposure?].

F. Barlesi, C. Doddoli, L. Greillier, 2003, Revue des maladies respiratoires.

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

R. Herbst, S. Dakhil, D. Camidge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

F. Barlesi, L. Bonello, M. Laine, 2020, Journal for ImmunoTherapy of Cancer.

Late pulmonary artery stump thrombosis with post embolic pulmonary hypertension after pneumonectomy

F. Barlesi, M. Reynaud‐Gaubert, R. Giudicelli, 2006, Thorax.

Multiple pulmonary nodules and underlying head and neck cancer.

B. Chetaille, F. Barlesi, B. Guelfucci, 2005, The Annals of thoracic surgery.

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

A. Drilon, G. Demetri, M. Ahn, 2021, ESMO Open.

Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer

K. Baumstarck, P. Auquier, L. Boyer, 2018, Quality of Life Research.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Severe COVID-19 in patients with hematological cancers presenting with viremia

P. Cournède, S. Foulon, F. Barlesi, 2021, Annals of Oncology.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

R. Govindan, R. Ramlau, M. Krzakowski, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1

M. Ahn, S. Walzer, F. Barlesi, 2011 .

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

M. Copin, D. Moro-Sibilot, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

R. Heist, K. Kelly, E. Vokes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

F. Barlesi, V. Moreno, E. Chartash, 2022, Cancer Immunology, Immunotherapy.

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.

F. André, J. Soria, F. Barlesi, 2021, Cancer discovery.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

[Bronchoscopy in the diagnosis of lung cancer: an evaluation of current practice].

F. Barlesi, C. Doddoli, H. Dutau, 2006, Revue des maladies respiratoires.

Author Correction: Caring for patients with cancer in the COVID-19 era

S. Fröhling, D. Jäger, J. Bergh, 2020, Nature Medicine.

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

D. Olive, B. Malissen, J. Nunès, 2022, bioRxiv.

134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2018 .

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

N. Girard, O. Molinier, J. Mazières, 2017 .

[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

B. Milleron, S. Laporte, J. Trédaniel, 2007, Revue des maladies respiratoires.

LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2017 .

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

M. Socinski, F. Cappuzzo, T. Mok, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016 .

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

M. Mencoboni, G. Banna, J. Daurès, 2019, PloS one.

Deciphering the response and resistance to immunecheckpoint inhibitors in lung cancer with artificial intelligence-based analysis: the pioneer and quantic joint-projects

F. Barlesi, J. Ciccolini, S. Benzekry, 2021 .

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC

F. Barlesi, J. Ciccolini, S. Benzekry, 2020, British Journal of Cancer.

Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)

N. Pavlakis, L. Crinò, N. Thatcher, 2008 .

Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

F. André, J. Soria, S. Foulon, 2020 .

Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM).

I. Soubeyran, L. Cerbone, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

O. Riesterer, C. Faivre-Finn, G. Zalcman, 2020 .

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

I. Amit, F. Ginhoux, L. Zitvogel, 2020, Cell.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study

Franck Morin, Patrick Merle, Pascal Auquier, 2018, European Respiratory Journal.

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

F. Ginhoux, J. Blay, L. Zitvogel, 2021, Cell Death & Differentiation.

Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.

F. Barlesi, A. Tasei, P. Astoul, 2006, Lung cancer.

Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Nicolas André, Laetitia Padovani, Joseph Ciccolini, 2016, Cancer research.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy

F. Barlesi, J. Ciccolini, F. Fina, 2020, Pharmaceutics.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

D. Coso, F. Barlesi, C. Chabannon, 2015, Virology.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation?

N. Lévy, F. Barlesi, P. Roll, 2018, Cells.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

F. Cappuzzo, S. Peters, J. Mazières, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer

R. Govindan, S. Novello, E. Juhász, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

N. Girard, Keunchil Park, L. Paz-Ares, 2018 .

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer

F. Barlesi, P. Tomasini, D. Barbolosi, 2019, Scientific Reports.

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

V. Torri, G. Minuti, H. Wakelee, 2020, The Lancet Oncology.

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

N. Segata, E. Le Chatelier, N. Pons, 2022, Nature Medicine.

Immune Oncology Biomarkers in Lung Cancer: an Overview

F. Barlesi, P. Tomasini, L. Greillier, 2020, Current Oncology Reports.

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

I. Bièche, B. Job, J. Soria, 2020, JTO clinical and research reports.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?

F. Barlesi, P. Hofman, 2019, Expert review of molecular diagnostics.

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy

F. Barlesi, P. Tomasini, F. Jean, 2017, Therapeutic advances in medical oncology.

Personalised medicine for nonsmall cell lung cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2017, European Respiratory Review.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Global histone modifications predict prognosis of resected non small-cell lung cancer.

G. Giaccone, F. Kruyt, F. Barlesi, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer

L. Urban, S. Ramalingam, V. Giranda, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Olivier Lantz, Laurence Zitvogel, Clotilde Théry, 2015, Oncoimmunology.

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

H. Blons, J. Merlio, F. Escande, 2020, Lung cancer.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

P. Jänne, A. Kohlmann, L. Crinò, 2017, JAMA.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

J. Mosser, J. Mazières, J. Sabourin, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New oncogenes drivers in lung cancer—new therapeutic targets

F. Barlesi, P. Tomasini, L. Greillier, 2016, Current Pulmonology Reports.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Arnaud Boyer, F. Barlesi, P. Tomasini, 2018, Journal of thoracic disease.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

E. Felip, L. Crinò, E. Vokes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

L. Zitvogel, G. Kroemer, E. Solary, 2021, Cell Death & Disease.

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) bio

H. Blons, J. Merlio, F. Escande, 2019, Lung cancer.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Nicolas André, Eddy Pasquier, Sébastien Benzekry, 2015, Seminars in cancer biology.

Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC

Paul Hofman, Amine Belaid, C. Marquette, 2013, PloS one.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

J. Pignon, B. Milleron, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

N. Hanna, C. Gridelli, E. Felip, 2017, Clinical lung cancer.

Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

D. Planchard, N. Chaput, F. Barlesi, 2023, European journal of cancer.

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

F. Barlesi, P. Tomasini, D. Barbolosi, 2021, medRxiv.

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

F. Barlesi, P. Tomasini, D. Barbolosi, 2021, Cancers.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

J. Mosser, H. Blons, J. Merlio, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

B. Milleron, M. Taron, G. Zalcman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Association for the Study of Lung Cancer (IASLC)

G. Scagliotti, I. Wistuba, C. Swanton, 2019, Annals of Oncology.

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

G. Scagliotti, L. Sequist, F. Shepherd, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

J. Soria, J. Mazières, G. Zalcman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Necitumumab for non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2015, Expert opinion on biological therapy.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

J. Neal, T. Lynch, I. Bondarenko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

T. Mok, E. Felip, S. Dakhil, 2021 .

[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

F. Barlesi, P. Tomasini, L. Greillier, 2011, Revue des maladies respiratoires.

Functional status in older patients with lung cancer: an observational cohort study

F. Barlesi, P. Tomasini, P. Villani, 2022, Supportive Care in Cancer.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung

R. Herbst, Z. Shun, V. Miller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

J. Desai, R. Govindan, J. Krauss, 2020, The New England journal of medicine.

Interventional Radiology for Local Immunotherapy in Oncology

T. de Baère, J. Soria, C. Robert, 2021, Clinical Cancer Research.

Video-assisted thoracoscopic management of recurrent primary spontaneous pneumothorax after prior talc pleurodesis: a feasible, safe and efficient treatment option.

F. Barlesi, R. Giudicelli, P. Fuentes, 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Rs488087 single nucleotide polymorphism as predictive risk factor for pancreatic cancers

D. Figarella-Branger, J. Iovanna, F. Barlesi, 2015, Oncotarget.

Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.

L. Urban, S. Ramalingam, V. Giranda, 2015 .

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

G. Ferretti, S. Lantuejoul, D. Moro-Sibilot, 2015, Targeted Oncology.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

G. Scagliotti, J. Milanowski, F. Shepherd, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

N. Girard, D. Planchard, G. Zalcman, 2015, Expert review of anticancer therapy.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

N. Girard, D. Planchard, G. Zalcman, 2014, Bulletin du cancer.

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

H. Groen, M. Ahn, J. Aerts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Un regard simple sur la biologie moléculaire du cancer bronchique : K-Ras A simple look at the molecular biology of lung cancer: K-Ras

F. Barlesi, H. Lenaa, R. Correa, 2010 .

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

R. Heist, K. Kelly, E. Vokes, 2021, JTO clinical and research reports.

ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.

Edward S. Kim, S. Ou, M. Ahn, 2021, Future oncology.

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Keunchil Park, J. Vansteenkiste, J. Yang, 2021, Lung cancer.

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

A. Tolcher, K. Kelly, M. Khasraw, 2021, Journal for ImmunoTherapy of Cancer.

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

N. Girard, Keunchil Park, L. Paz-Ares, 2020, Frontiers in Oncology.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small‐Cell Lung Cancer: Focus on 2‐Year Overall Survival and Continuum of Care

C. Obasaju, L. Paz-Ares, F. Barlesi, 2018, Clinical lung cancer.

Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?

F. Barlesi, P. Tomasini, L. Greillier, 2013, Current Respiratory Care Reports.

[Management of patients with resistance to EGFR-TKI].

F. Barlesi, 2011, Revue de pneumologie clinique.

[Systemic treatment of brain metastases from lung cancer].

F. Barlesi, B. Besse, J. Spano, 2015, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility

J. Blay, Benoît R. Kloeckner, L. Zitvogel, 2021, medRxiv.

The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

J. Blay, Benoît R. Kloeckner, L. Zitvogel, 2022, Cancer discovery.

Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma

F. Barlesi, L. Ouafik, K. Mabrouk, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service

F. Barlesi, M. Gouitaa, L. Greillier, 2018, Journal of clinical pharmacy and therapeutics.

Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients

G. Wainrib, J. Pesquet, E. Pronier, 2021, Nature Communications.

A. Chella, M. Ahn, Joo‐Hang Kim, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

J. Blay, G. Ferretti, J. Mazières, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

N. Chaput, C. Balleyguier, F. Barlesi, 2020, Annals of Oncology.

Targeted therapies in malignant pleural mesothelioma: a review of clinical studies

F. Barlesi, L. Greillier, S. Marco, 2011, Anti-cancer drugs.

OncoAlert Round Table Discussions: The Global COVID-19 Experience

T. Choueiri, S. Peters, N. Personeni, 2021, JCO global oncology.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

M. Socinski, F. Cappuzzo, T. Mok, 2019, The Lancet. Respiratory medicine.

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.

D. Planchard, N. Chaput, J. Mazières, 2021, Lung cancer.

Ipilimumab: its potential in non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2012, Therapeutic advances in medical oncology.

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

C. Mascaux, F. Barlesi, P. Tomasini, 2019, Clinical lung cancer.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

A. Drilon, T. Wilson, C. Chung, 2019, The Lancet. Oncology.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.

H. Groen, D. Planchard, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)

R. Govindan, S. Novello, E. Juhász, 2016 .

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

N. André, E. Pasquier, C. Mascaux, 2018, European Respiratory Review.

Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

D. Carbone, F. Barlesi, M. Reck, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

M. Ahn, D. Camidge, Geoffrey Liu, 2020 .

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

O. Molinier, J. Mazières, K. Leroy, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).

C. Dooms, G. Shapiro, F. Barlesi, 2021 .

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.

F. Barlesi, D. Breen, 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

C. Mascaux, F. Barlesi, P. Tomasini, 2016, Therapeutic advances in medical oncology.

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

L. Urban, S. Ramalingam, V. Giranda, 2016, Clinical Cancer Research.

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

F. Barlesi, J. Spano, P. Metellus, 2012, Radiation oncology.

[The ban on smoking in public places (Decree No. 2006-1386 of 15th November 2006): Impact over 12 months on smoking status of hospital nurses].

F. Barlesi, M. Lehucher-Michel, K. Baumstarck-Barrau, 2010, Revue des maladies respiratoires.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.

J. Pujol, G. Zalcman, D. Moro-Sibilot, 2014 .

Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial

O. Molinier, J. Mazières, G. Zalcman, 2020, Clinical Cancer Research.

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.

O. Riesterer, C. Faivre-Finn, A. Dunant, 2021, The Lancet. Oncology.

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

Jean-Philippe Spano, David Azria, Philippe Metellus, 2012, Radiation Oncology.

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.

L. Cerbone, F. Barlesi, L. Lacroix, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis

V. Velcheti, H. Borghaei, M. Schuler, 2021, Pneumologie.

Imaging: towards a global solution to overcome the cancer pandemic.

C. Balleyguier, N. Lassau, F. Barlesi, 2021, The Lancet. Oncology.

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

G. Bepler, G. Scagliotti, Keunchil Park, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

S. Domchek, Sang-We Kim, F. Barlesi, 2017 .

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

F. Barlesi, R. Gervais, H. Léna, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

L. Sequist, L. Paz-Ares, D. Tan, 2020 .

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer

S. Taillibert, F. Barlesi, J. Spano, 2014, International journal of molecular sciences.

Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study

R. Soffietti, F. Barlesi, P. Tomasini, 2020, Oncotarget.

Manufacture of adoptive cell therapies at academic cancer centers: Scientific, safety and regulatory challenges.

F. André, I. Svane, K. Saini, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

High serum vitamin B12 levels associated with C-Reactive Protein (BCI) in older cancer patients.

S. Salas, G. Gentile, F. Barlesi, 2020, The oncologist.

Anaphylactic reaction to pemetrexed: a case report.

F. Barlesi, P. Tomasini, D. Charpin, 2014, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Venobronchial Fistula: An Unusual Complication of Long-Term Central Venous Access

F. Barlesi, R. Giudicelli, C. Doddoli, 2006, Respiration.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients

N. André, C. Mascaux, F. Barlesi, 2017, Oncotarget.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support

Sébastien Benzekry, Joseph Ciccolini, Dominique Barbolosi, 2015, Proceedings of the National Academy of Sciences.

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

P. Tiberghien, F. Barlesi, F. Griscelli, 2021, Annals of Oncology.

Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study

F. Barlesi, S. Honoré, F. Duffaud, 2020, Clinical interventions in aging.

[Quality of life: attitudes and perspectives of doctors in a thoracic oncology regional care network].

P. Auquier, F. Barlesi, C. Doddoli, 2006, Sante publique.

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

K. Baumstarck, P. Auquier, O. Chinot, 2012, European journal of cancer.

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

F. Barlesi, C. Chouaid, A. Vergnenègre, 2011, British Journal of Cancer.

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

F. Barlesi, P. Fournel, C. Chouaid, 2007, Lung cancer.

Caring for patients with cancer in the COVID-19 era

S. Fröhling, D. Jäger, J. Bergh, 2020, Nature Medicine.

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

N. Chaput, F. André, J. Soria, 2020, Nature Cancer.

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

F. Barlesi, P. Souquet, P. Fournel, 2007, Targeted Oncology.

Octogenarians treated for thoracic and lung cancers: Impact of comprehensive geriatric assessment.

F. Barlesi, P. Tomasini, P. Villani, 2020, Journal of geriatric oncology.

High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer

S. Salas, F. Barlesi, P. Suchon, 2020 .

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

V. Torri, N. Reinmuth, H. Wakelee, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.

Anti-TIGIT therapies for solid tumors: a systematic review

F. Barlesi, C. Parisi, A. Rousseau, 2023, ESMO open.

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

B. Cho, F. Barlesi, T. Kim, 2020 .

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

R. Heist, K. Kelly, E. Vokes, 2019, Journal of Clinical Oncology.

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

A. Ardizzoni, C. Bossen, F. Barlesi, 2022, Annals of Oncology.

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report

N. Chaput, C. Balleyguier, F. Barlesi, 2020 .

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

B. Asselain, D. Moro-Sibilot, F. Barlesi, 2020, Oncoimmunology.

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases

F. Barlesi, P. Tomasini, L. Greillier, 2019, Therapeutic advances in respiratory disease.

Fatal pulmonary haemorrhage from a mycotic pulmonary artery aneurysm.

B. Chetaille, F. Barlesi, J. Gaubert, 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

J. Mosser, F. Penault-Llorca, J. Soria, 2013 .

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

F. Barlesi, P. Fournel, R. Descourt, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Functional status in a geriatric oncology setting: A review.

F. Barlesi, P. Villani, O. Guerin, 2019, Journal of geriatric oncology.

[Management of brain metastases for lung cancer patients].

Jean Régis, Jean-Philippe Spano, David Azria, 2013, Bulletin du cancer.

Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.

A. Italiano, F. Barlesi, L. Lacroix, 2023, JCO precision oncology.

COVID-19 management in a cancer center: the ICU storm

F. Barlesi, F. Scotté, A. Stoclin, 2020, Supportive Care in Cancer.

Challenges in lung cancer therapy during the COVID-19 pandemic

C. Gridelli, S. Peters, J. Soria, 2020, The Lancet Respiratory Medicine.

Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management.

Pascal Thomas, F. Barlesi, A. Loundou, 2007, The Journal of thoracic and cardiovascular surgery.

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients

F. Barlesi, C Faivre, R El Cheikh, 2017, British Journal of Cancer.

Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys

F. Barlesi, S. Temam, A. Moya-Plana, 2022, ESMO Open.

Use and impact of the G8 score in older patients with thoracic and lung cancers

F. Barlesi, P. Villani, P. Thomas, 2021, European Geriatric Medicine.

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.

F. Barlesi, P. Tomasini, P. Villani, 2020, Clinical lung cancer.

Elderly selection on geriatric index assessment.

C. Mascaux, F. Barlesi, P. Tomasini, 2016, Annals of Translational Medicine.

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol

N. André, F. Barlesi, B. Lacarelle, 2016, BMC Cancer.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

G. Zalcman, D. Moro-Sibilot, F. Barlesi, 2015, European Respiratory Journal.

Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.

F. Barlesi, S. Ederhy, L. Bonello, 2016, International journal of cardiology.

A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS)

G. Giaccone, E. Smit, E. Felip, 2008 .

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

F. Barlesi, P. Tomasini, J. Ciccolini, 2022, Cancer Chemotherapy and Pharmacology.

Metronomics chemotherapy: time for computational decision support

N. André, F. Barlesi, B. Lacarelle, 2014, Cancer Chemotherapy and Pharmacology.

LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

P. Auquier, J. Mazières, F. Barlesi, 2020 .

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)

E. Devin, J. Lafitte, J. Trédaniel, 2017 .

OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

P. Jänne, Ying Cheng, E. Smit, 2021 .

Impact of COVID-19 Pandemic on Cancer Research

L. Zon, D. Tuveson, A. Ribas, 2020, Cancer Cell.

BJRD16061 1..4

F. Barlesi, J. Ciccolini, D. Taieb, 2016 .

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2016, International journal of molecular sciences.

93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

E. Fadel, D. Planchard, J. Adam, 2020 .

ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)

A. Shaw, J. Ahn, R. Dziadziuszko, 2019, Pneumologie.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

F. Barlesi, C. Chouaid, J. Barth, 2018, Lung cancer.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

L. Urban, E. Felip, L. Paz-Ares, 2019 .

Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

N. Segata, L. Zitvogel, D. Planchard, 2021 .

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study

D. Planchard, F. Barlesi, B. Besse, 2018, Journal of Thoracic Oncology.

P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR RES

E. Felip, D. Tan, Dae-Ho Lee, 2017 .

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

H. Wakelee, C. Chiu, L. Chow, 2019, Annals of Oncology.

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

P. Wen, H. Wakelee, L. Chow, 2019, Annals of Oncology.

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience

F. Barlesi, P. Tomasini, L. Greillier, 2016, Therapeutic advances in respiratory disease.

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients.

D. Planchard, S. Michiels, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?

P. Froguel, P. Marquet, F. Barlesi, 2015, Therapie.

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC

F. Barlesi, J. Ciccolini, S. Benzekry, 2020, British Journal of Cancer.

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).

B. Milleron, G. Zalcman, D. Moro-Sibilot, 2010, Lung cancer.

A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer

O. Mir, F. André, J. Soria, 2020, European Journal of Cancer.

Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.

A. Drilon, T. Wilson, F. Wu, 2021 .

CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

J. Krauss, T. Burns, D. Hong, 2020, Journal of Clinical Oncology.

FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study

J. Mosser, D. Planchard, J. Merlio, 2021 .

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

C. Henschke, L. Crinò, F. Barlesi, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.

J. Daurès, J. Pujol, F. Barlesi, 2006, Lung cancer.

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

F. Barlesi, C. Doddoli, J. Kleisbauer, 2004, British Journal of Cancer.

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

O. Molinier, D. Moro-Sibilot, F. Barlesi, 2020, Clinical lung cancer.

Computational modeling reveals dynamics of brain metastasis in non-small cell lung cancer and provides a tool for personalized therapy

F. Barlesi, P. Tomasini, D. Barbolosi, 2018, bioRxiv.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.

F. Cappuzzo, Ji-Youn Han, F. Barlesi, 2022, Journal of Clinical Oncology.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

[Hypersensitivity to carboplatin. An effect of generic drugs?].

F. Barlesi, A. Magnan, Y. Gernez, 2006, Revue des maladies respiratoires.

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).

H. Groen, L. Sequist, E. Smit, 2012 .

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

V. Torri, H. Wakelee, V. Pancaldi, 2020, Cancer Cell.

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.

V. Torri, H. Wakelee, V. Pancaldi, 2020 .

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

V. Torri, H. Wakelee, V. Pancaldi, 2020, Cancer Cell.

[Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].

M. Richard, F. Barlesi, C. Gaudy-Marqueste, 2007, Revue des maladies respiratoires.

How to Promote and Organize Clinical Research in Lung Cancer

R. Herbst, J. Mazières, G. Zalcman, 2018 .

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

F. Barlesi, P. Tomasini, L. Greillier, 2019, Translational lung cancer research.

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

S. Michiels, J. Soria, F. Barlesi, 2021, Cancer Cell.

Functional status in older patients with cancer.

S. Salas, F. Barlesi, P. Suchon, 2021, Journal of geriatric oncology.

Impact of blood transfusions on outcome after pneumonectomy for thoracic malignancies

F. Barlesi, P. Michelet, R. Giudicelli, 2007, European Respiratory Journal.

Ang1 and Tie2 Are Predictive Biomarkers for Bevacizumab—Letter

F. Barlesi, B. Lacarelle, J. Ciccolini, 2015, Clinical Cancer Research.

Dyadic effects of coping strategies, time perspectives, and personality on the quality of life of cancer patients and their caregivers

K. Baumstarck, P. Auquier, O. Chinot, 2018, Psycho-oncology.

Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

F. Ciardiello, F. Barlesi, M. Ballinger, 2017, Pneumologie.

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).

M. Ahn, T. Mok, E. Felip, 2019, Journal of Clinical Oncology.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

A. Drilon, J. Mazières, C. Mascaux, 2018 .

3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial

F. Barlesi, F. Vély, L. Ghezali, 2022, Immuno-Oncology and Technology.

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

F. Barlesi, P. Fournel, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01

P. Jänne, E. Smit, E. Felip, 2021 .

375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

M. Socinski, S. Novello, P. Dubray-Longeras, 2020 .

MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients

N. Girard, O. Molinier, F. Barlesi, 2019, Journal of Thoracic Oncology.

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

Keunchil Park, D. Gandara, L. Fehrenbacher, 2017 .

Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.

Edward S. Kim, M. Ahn, S. Novello, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Another Drawback for Clinical Trials Entry Criteria.

F. Barlesi, Maeva Andriantsoa, Mathieu Barbolosi, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

E. Felip, B. Cho, Dae-Ho Lee, 2022, The oncologist.

Multicystic kidney disease: a complication of crizotinib.

F. Barlesi, S. Burtey, P. Souteyrand, 2015, Diagnostic and interventional imaging.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma

Sébastien Benzekry, Joseph Ciccolini, Dominique Barbolosi, 2017, CPT: pharmacometrics & systems pharmacology.

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

S. Digumarthy, G. Scagliotti, L. Landi, 2023, Cancer discovery.

OA 16.03 Recurrences and 2nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery

N. Girard, J. Lafitte, J. Muir, 2017 .

[Impact of a brochure on pain destined for thoracic oncology patients].

P. Auquier, F. Barlesi, F. Duffaud, 2004, Presse medicale.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

J. Mosser, H. Blons, J. Merlio, 2017 .

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.

E. Felip, D. Planchard, V. Ludovini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial

I. Bièche, J. Adam, J. Soria, 2020 .

IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC).

K. Goto, V. Papadimitrakopoulou, F. Barlesi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

C. Henschke, L. Crinò, F. Barlesi, 2012 .

Targeted therapies in non-small-cell lung cancer (NSCLC): how to proceed to aim at the good target?

F. Barlesi, 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Combinatorial Immunotherapy Strategies: most Gods throw Dice, but fate plays Chess.

N. André, F. Barlesi, J. Ciccolini, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

A. Drilon, R. Doebele, F. Barlesi, 2019, Annals of Oncology.

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

R. Herbst, D. Camidge, F. Barlesi, 2021, Annals of Oncology.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

J. Vernejoux, F. Barlesi, P. Fournel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.

P. Wen, M. J. van den Bent, H. Wakelee, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

A. Dingemans, S. Ou, F. Barlesi, 2016 .

[Acute pericarditis of unusual etiology].

F. Barlesi, E. Garnotel, E. Auvray, 1998, Revue de pneumologie clinique.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN).

J. Soria, J. Mazières, D. Moro-Sibilot, 2013 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

P. Hegde, J. von Pawel, E. Juhász, 2018, The oncologist.

IMpower150: Exploratory analysis of brain metastases development.

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

[Validation of the French version of the Princess Margaret Hospital Patient Satisfaction with their Doctor Questionnaire].

A. Loundou, P. Auquier, F. Barlesi, 2006, Revue des maladies respiratoires.

[Acute respiratory distress syndrome following inhalation of barium sulfate].

B. Chetaille, L. Papazian, F. Barlesi, 2005, Revue des maladies respiratoires.

“I think it’s a bit early for now”: impact of psychological factors on drafting advance directives among cancer patients

L. Dany, P. Cannone, F. Barlesi, 2018, Journal of psychosocial oncology.

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer

Jie Yang, E. Felip, M. Satouchi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours

F. Barlesi, F. Ghiringhelli, B. Hackanson, 2020 .

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

M. Socinski, T. Mok, D. Moro-Sibilot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot

R. Sun, F. Barlesi, S. Ammari, 2021, International Journal of Radiation Oncology*Biology*Physics.

Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?

N. André, F. Barlesi, J. Ciccolini, 2020, JCO precision oncology.

Postoperative follow-up of lung cancer: Randomized trial comparing two follow-up programs in completely resected non-small cell lung cancer (IFCT-0302).

E. Devin, J. Lafitte, J. Trédaniel, 2012 .

Survival and postoperative complication in daily practice after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer.

B. Chetaille, F. Barlesi, R. Giudicelli, 2003, Interactive cardiovascular and thoracic surgery.

Institutional review - Thoracic general Survival and postoperative complication in daily practice after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer

B. Chetaille, F. Barlesi, R. Giudicelli, 2003 .

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies ( NP 28673 1 and NP 28761 ) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer

Jie Yang, R. Govindan, A. Shaw, 2017 .

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01).

F. Barlesi, R. Gervais, H. Léna, 2010 .

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.

J. Pignon, B. Milleron, J. Soria, 2015 .

Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.

P. Paik, E. Felip, J. Grilley-Olson, 2014 .

Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

B. Cho, F. Barlesi, F. Ghiringhelli, 2022, Journal of Clinical Oncology.

OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study

O. Molinier, G. Zalcman, P. Dumont, 2017 .

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

N. Girard, E. Felip, Dong-Wan Kim, 2021 .

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.

Edward S. Kim, S. Ou, M. Ahn, 2019, Journal of Clinical Oncology.

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study

F. Barlesi, C. Touzeau, C. Massard, 2023, ESMO open.

Immunologically effective dose: a practical model for immuno-radiotherapy

F. Barlesi, X. Muracciole, D. Barbolosi, 2018, Oncotarget.

Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study

F. Barlesi, R. Giorgi, P. Vanelle, 2020, Tumori.

Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon?

F. Barlesi, V. Moutardier, L. Greillier, 2010, Lung Cancer.

Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study

W. Weeks, B. Ventelou, F. Barlesi, 2020, PloS one.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid

F. Barlesi, P. Tomasini, L. Ouafik, 2018, Clinical chemistry and laboratory medicine.

Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.

E. Felip, A. Santoro, A. Navarro, 2022, Lung cancer.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

H. Groen, M. Ahn, J. Aerts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

F. Barlesi, R. Gervais, H. Léna, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted therapies in malignant pleural mesothelioma: a review of clinical studies

F. Barlesi, L. Greillier, S. Marco, 2011, Anti-cancer drugs.

Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

V. Torri, H. Wakelee, S. Peters, 2020 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

P. Hegde, J. von Pawel, E. Juhász, 2018, The oncologist.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

D. Olive, B. Malissen, J. Nunès, 2023, Journal for ImmunoTherapy of Cancer.

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

M. Socinski, T. Mok, F. Barlesi, 2020 .

1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC

D. Gandara, J. Mazières, C. Matheny, 2020 .

Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

J. Mazières, R. Rosell, F. Barlesi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

F. Barlesi, J. Mochel, J. Ciccolini, 2019, bioRxiv.

[Radiotherapy for oligometastatic non-small cell lung cancer patients].

F. Barlesi, C. Le Péchoux, A. Levy, 2021, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives

J. Mazières, F. Barlesi, B. Besse, 2012 .

Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times

P. Auquier, F. Barlesi, F. Morin, 2018, European Respiratory Journal.

[Tolerance of fiberoptic bronchoscopy by self-administered questionnaire: in the words of the patients].

F. Barlesi, C. Doddoli, L. Greillier, 2003, Revue des maladies respiratoires.

P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)

F. Barlesi, H. Mann, C. Aggarwal, 2022, Journal of Thoracic Oncology.

Tumor relapse after thoracic surgery?

F. Barlesi, P. Tomasini, P. Thomas, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis

A. Drilon, M. Ahn, R. Doebele, 2020 .

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

F. Barlesi, C. Chouaid, J. Barth, 2018, Lung cancer.

Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC).

E. Felip, A. Santoro, A. Navarro, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to B.M. Strebel.

H. Groen, M. Ahn, J. Aerts, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.

R. Heist, K. Kelly, D. Camidge, 2019, Journal of Clinical Oncology.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

J. Trédaniel, F. Barlesi, M. Wislez, 2022, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

T. Lynch, I. Bondarenko, F. Barlesi, 2010 .

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials Lung Cancer Coronavirus Disease Clinical

G. Scagliotti, H. Wakelee, T. Mitsudomi, 2022 .

Adrenal surgery for oligometastatic tumors improves survival in selected cases.

F. Barlesi, P. Tomasini, F. Sebag, 2017, Journal of visceral surgery.

89PDResults from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC

D. Gandara, S. Gadgeel, F. Barlesi, 2017 .